Browsing Tag
zumilokibart
3 posts
AbbVie (ABBV) raises 2026 revenue guidance as Skyrizi and Rinvoq lift Q2 revenue to $17bn
AbbVie posted Q2 2026 revenue of $16.99 billion as Skyrizi crossed $5.5bn quarterly, but the pending $10.9bn Apogee deal trimmed 2026 adjusted EPS guidance.
AbbVie weighs $10.9bn Apogee deal to strengthen its next immunology growth cycle
AbbVie may pay $10.9 billion for Apogee Therapeutics before Phase 3. Read what the reported deal could mean for immunology growth and ABBV stock.
Can a new IL-13 drug quietly challenge Dupixent’s dominance in eczema treatment?
Apogee Therapeutics’ APEX data could reshape eczema treatment competition. Discover what it means for Dupixent, Ebglyss, and investors.